SMALL CELL LUNG CANCER

This study tests a new drug called SKB264 in people with advanced solid tumors (like lung, breast, or ovarian cancer) that have not responded to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 1,410 participants will receive t…

This study tests whether adding chest radiation to maintenance durvalumab can help people with extensive-stage small cell lung cancer live longer without the disease getting worse. About 46 participants will first receive standard chemo plus durvalumab, then those whose cancer re…

This study is for people with small cell or non-small cell lung cancer whose cancer has worsened after initial treatment. It tests a combination of three drugs: ADI-PEG 20, gemcitabine, and docetaxel. The first part finds the safest dose, and the second part checks how well the c…

This study tests whether the drug tarlatamab can delay cancer growth and extend life in people with limited-stage small cell lung cancer who have completed chemotherapy and radiation. About 404 adults will receive either tarlatamab or a placebo. The goal is to see if tarlatamab h…

This study tests whether adding the drug AZD2811 to the immunotherapy durvalumab can help keep extensive-stage small-cell lung cancer under control after initial treatment. About 31 adults with this advanced cancer will receive the combination as maintenance therapy. The goal is …

This phase 3 study tests whether adding lurbinectedin to atezolizumab as maintenance therapy helps people with extensive-stage small-cell lung cancer live longer without their cancer growing. Participants must have stable disease or better after initial chemotherapy plus atezoliz…

This early-stage study tests a combination of three drugs (tarlatamab, YL201, and an anti-PD-L1) in about 200 adults with extensive stage small cell lung cancer that has worsened after initial treatment. The main goal is to check safety and side effects, while also measuring how …

This early-phase study tests an experimental oral drug, BBI-355, in people with advanced solid tumors (like certain breast, ovarian, lung, and other cancers) that have extra copies of certain genes (oncogene amplifications). The study aims to find the safest dose and see if BBI-3…

This study tests whether adding immunotherapy drugs (durvalumab alone or with tremelimumab) after standard chemoradiation can help keep limited-stage small cell lung cancer from growing or coming back. About 730 adults whose cancer did not worsen after initial treatment received …

This study tests a new drug called PF-07104091 in people with advanced small cell lung, ovarian, or breast cancers that have not responded to prior treatments. The goal is to find the safest dose and see if the drug can shrink tumors when used alone or with other cancer medicines…

This study compares a new drug, BL-B01D1, to the standard treatment topotecan in people whose small cell lung cancer has returned after initial therapies. About 722 adults with recurrent disease will be randomly assigned to one of the two treatments. The main goal is to see if BL…

This study tests a combination of two drugs—nivolumab (an immunotherapy that helps the immune system fight cancer) and temozolomide (a chemotherapy drug)—in people with small-cell lung cancer that has returned or stopped responding to treatment, or advanced neuroendocrine tumors.…

This study tests a new drug called HPN328, alone or with other medicines, in people with advanced small-cell lung cancer or neuroendocrine cancer that has DLL3 protein. The goal is to find the safest dose and see how well the body handles it. About 232 adults will take part in th…

This study is for people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease has progressed after standard immunotherapy. It tests a new drug combination designed to boost the immune system to fight cancer. About 40 participants will receive the experime…

This early-phase study tests a new treatment called AMG 119 for adults with small cell lung cancer that has returned or not responded to standard chemotherapy. The treatment uses specially engineered immune cells (CAR T cells) to attack the cancer. The main goals are to check saf…

This early-phase trial tests whether adding chest radiation followed by immunotherapy drugs (durvalumab alone or with tremelimumab or olaparib) can help control extensive-stage small cell lung cancer after initial chemotherapy. About 25 adults whose cancer did not worsen after fi…

This study tests a drug called XmAb20717 in 140 adults with advanced rare cancers, such as mesothelioma and Hodgkin's lymphoma. The goal is to see if the drug can shrink tumors and how safe it is. The trial is currently on hold.

This study tests an oral drug called AL8326 in people with advanced small cell lung cancer that has returned or spread after at least one prior treatment. The goal is to find the best dose and see if it can shrink tumors or slow cancer growth. About 36 adults with good performanc…

This study tests a pill called abemaciclib in people with specific lung cancers (small cell, large cell neuroendocrine, and related types) that have stopped responding to chemotherapy. The goal is to see if the drug can shrink tumors and how safe it is. 14 participants will recei…

This study tests whether adding tarlatamab to durvalumab helps people with extensive-stage small-cell lung cancer live longer than durvalumab alone. About 563 adults who finished initial chemotherapy and durvalumab without their cancer getting worse will take part. The main goal …

This study tests a new drug called BNT327 combined with chemotherapy in people with a hard-to-treat type of lung cancer (small-cell lung cancer). About 110 adults will take part, some getting the combo as their first treatment and others after earlier treatments stopped working. …

This study tests whether adding the immunotherapy drug atezolizumab after standard chemo-radiotherapy helps people with limited-stage small-cell lung cancer live longer. About 212 participants will receive either atezolizumab or no additional treatment. The goal is to see if this…

This study tests a new type of PET/CT scan that uses a radioactive tracer called 68Ga-DOTATOC to find neuroendocrine tumors (NETs) and other related cancers. The scan targets a molecule found in high amounts on these tumor cells. Researchers want to see if this scan is safer and …

This study tests a supportive care program for adults who have finished treatment for lung cancer or mesothelioma. The goal is to help improve quality of life during the transition to regular check-ups. About 21 participants will try the program, and researchers will see if it is…

This study looks at two ways to give radiation to people with cancer that has spread to the brain. All participants are also receiving immunotherapy. The standard approach gives a single high dose of radiation, while the experimental approach gives a lower dose over a few days. T…

This study follows over 2,700 patients with bladder, lung, or liver cancer who received the drug atezolizumab as part of their normal care. Researchers are tracking how long patients live and how well the drug controls the cancer outside of strict clinical trial settings. The goa…